Cargando…

Interchangeability of Biosimilars: Overcoming the Final Hurdles

Detalles Bibliográficos
Autores principales:	Barbier, Liese, Vulto, Arnold G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8578114/ https://www.ncbi.nlm.nih.gov/pubmed/34727332 http://dx.doi.org/10.1007/s40265-021-01629-4

Ejemplares similares

European Stakeholder Learnings Regarding Biosimilars: Part I—Improving Biosimilar Understanding and Adoption
por: Barbier, Liese, et al.
Publicado: (2020)

European Stakeholder Learnings Regarding Biosimilars: Part II—Improving Biosimilar Use in Clinical Practice
por: Barbier, Liese, et al.
Publicado: (2020)

Biosimilar and interchangeable: Inseparable scientific concepts?
por: de Mora, Fernando, et al.
Publicado: (2019)

The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars
por: Barbier, Liese, et al.
Publicado: (2019)

An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?
por: Moorkens, Evelien, et al.
Publicado: (2020)

Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking
por: Barbier, Liese, et al.
Publicado: (2022)

Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care
por: Vandenplas, Yannick, et al.
Publicado: (2022)

The Automatic Substitution of Biosimilars: Definitions of Interchangeability are not Interchangeable
por: Afzali, Anita, et al.
Publicado: (2021)

Knowledge and perception of biosimilars in ambulatory care: a survey among Belgian community pharmacists and physicians
por: Barbier, Liese, et al.
Publicado: (2021)

Off-Patent Biologicals and Biosimilars Tendering in Europe—A Proposal towards More Sustainable Practices
por: Barbier, Liese, et al.
Publicado: (2021)

DRUG REPURPOSING—Overcoming the translational hurdles to clinical use
por: Martin, Jennifer H., et al.
Publicado: (2019)

The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review
por: Barbier, Liese, et al.
Publicado: (2020)

Regulatory Information and Guidance on Biosimilars and Their Use Across Europe: A Call for Strengthened One Voice Messaging
por: Barbier, Liese, et al.
Publicado: (2022)

Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies
por: Moorkens, Evelien, et al.
Publicado: (2016)

Focus on biosimilar etanercept – bioequivalence and interchangeability
por: Cantini, Fabrizio, et al.
Publicado: (2018)

Biosimilar and Follow-on Insulin: The Ins, Outs, and Interchangeability
por: White, John, et al.
Publicado: (2018)

Biologicals and Biosimilars in Hematology: The Case of Rituximab
por: Vulto, Arnold G.
Publicado: (2019)

Hurdles of publication: to authors to overcome
por: Mohammadhassanzadeh, Hafez, et al.
Publicado: (2014)

Interchangeability of Biosimilars: What Level of Clinical Evidence is Needed to Support the Interchangeability Designation in the United States?
por: Alvarez, Daniel F., et al.
Publicado: (2020)

An Update Review of Biosimilars of Adalimumab in Psoriasis – Bioequivalence and Interchangeability
por: Zhou, Xin, et al.
Publicado: (2021)

Biosimilarity and Interchangeability: Principles and Evidence: A Systematic Review
por: McKinnon, Ross A., et al.
Publicado: (2018)

New hurdles for translational research
por: Dowsett, Mitch
Publicado: (2000)

Defining the critical hurdles in cancer immunotherapy
por: Fox, Bernard A, et al.
Publicado: (2011)

Esophageal Cancer: Overcome the Hurdles and Reach for the Cure
por: Kim, Hong Kwan, et al.
Publicado: (2020)

Standardisation and controls, why can’t we overcome the hurdles?
por: Niesters, Hubert G.M., et al.
Publicado: (2004)

Risk management of biosimilars in oncology: each medicine is a work in progress
por: Vulto, Arnold G., et al.
Publicado: (2012)

The process defines the product: what really matters in biosimilar design and production?
por: Vulto, Arnold G., et al.
Publicado: (2017)

Physician‒Scientists in Italian Dermatology: Hurdles and Perspectives
por: Pincelli, Carlo, et al.
Publicado: (2021)

CAR-T cell therapy in myeloma: hopes and hurdles
por: Harousseau, Jean Luc
Publicado: (2023)

Bioboxes: standardised containers for interchangeable bioinformatics software
por: Belmann, Peter, et al.
Publicado: (2015)

Interchangeability of biosimilars: A study of expert views and visions regarding the science and substitution
por: Druedahl, Louise C., et al.
Publicado: (2022)

Childhood immunisation in South Asia – overcoming the hurdles to progress
por: Hasman, Andreas, et al.
Publicado: (2016)

CRISPR-Cas9 for in vivo Gene Therapy: Promise and Hurdles
por: Dai, Wei-Jing, et al.
Publicado: (2016)

Major hurdles of immune-checkpoint inhibitors in pancreatic ductal adenocarcinoma
por: Akhuba, Liia, et al.
Publicado: (2023)

Economic evaluation of biosimilars for reimbursement purposes – what, when, how?
por: Moorkens, Evelien, et al.
Publicado: (2020)

Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective
por: Kurki, Pekka, et al.
Publicado: (2021)

Knowledge, Attitude, and Practice Towards Biosimilars and Interchangeable Products: A Prescriptive Insight by the Pharmacists
por: Shakeel, Sadia, et al.
Publicado: (2020)

Biosimilar Pegfilgrastim: Improving Access and Optimising Practice to Supportive Care that Enables Cure
por: Cornes, Paul, et al.
Publicado: (2020)

Pharmacogenomics Implementation and Hurdles to Overcome; In the Context of a Developing Country
por: Ayati, Nayyereh, et al.
Publicado: (2021)

BEACON: A Summary Framework to Overcome Potential Reimbursement Hurdles
por: Dunlop, William C. N., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_l71210jrposn588lpnu8t7k2u6